Pharma Intelligence Informatics Solutions Video

おすすめのニュース＆レポート

• In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

  ESG In 2020: Not A Tick-Box Exercise But A Strategic Opportunity

  By William Looney

  The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.

  Topics Strategy

  View Article

• Generics Bulletin: ジェネリック＆バイオシミラーニュース

  Celltrion Sets Out Strategy For China

  By David Wallace

  Celltrion has unveiled plans to construct a biologics plant in Wuhan, China, as well as setting up a direct sales network in the country, as part of its wider global strategy that also involves launching a new biosimilar every year to 2030.

  Topics Strategy

  View Article

• Generics Bulletin: ジェネリック＆バイオシミラーニュース

  Biocon Biologics Gets True North Investment

  By Anju Ghangurde

  Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

  Topics Deal trends Strategy

  View Analysis